



**COBATEST**  
NETWORK



## Launch of COBATEST Network collaboration with AIDS Action Europe

20 November 2018

l'Agència de Salut Pública de Catalunya

Carrer de Roc Boronat, Barcelona

Topic	Comments	Action
<b>CHAFEA Projects</b>	Presentation available	
<b>AIDS Action Europe</b>	Presentation available	
<b>Objectives of CEEISCAT and AAE</b>	<p><b>Common objectives for Network</b></p> <ol style="list-style-type: none"> <li>1. Consolidation and sustainability of the network</li> <li>2. Increase coverage and geographical scope.</li> </ol> <p><b>CEEISCAT objectives in collaboration</b></p> <ol style="list-style-type: none"> <li>1. Formalise collaboration between public health academia and civil society</li> <li>2. Incorporate components other than M&amp;E (Capacity building, dissemination, advocacy)</li> <li>3. Fundraising and spine projects.</li> <li>4. Increase usefulness of data</li> <li>5. Increase political influence</li> </ol> <p><b>AAE objectives in collaboration</b></p> <ol style="list-style-type: none"> <li>1. Our philosophy: Collaboration strengthens the network (Creation or maintaining of sub-networks increases collaboration of AAE Members)</li> <li>2. Community based testing needs to be boosted and supported – key thematic area for AAE</li> <li>3. Advocacy tool for cost-effectiveness of CBVCT to use at national level</li> </ol>	Define objectives in document for discussion at next Steering Committee meeting <i>March</i>

The COBATEST Network and this meeting receive funding from the European Commission 3rd Health Programme and a Gilead grant



Co-funded by  
the Health Programme  
of the European Union



**GILEAD**

<p><b>Dublin Declaration Monitoring</b></p>	<p>Presentation not yet available. Please contact Rosalie Hayes with questions <a href="mailto:rosalie.hayes@nat.org.uk">rosalie.hayes@nat.org.uk</a></p> <p>RH data should be interpreted with caution e.g. underreporting of MSM as relies on self-reporting</p> <p>RH notes the presence of National AIDS Trust in the Dublin Declaration Monitoring process increases civil society presence.</p> <p>CK comm organisations send data to their national focal points but then do not know how/if data has been used in the monitoring.</p> <p>MG some Polish data and testing activity is not reflected in Dublin Declaration Monitoring.</p>	<p>Slides will be shared with members when approved by ECDC</p>
<p><b>Steering Committee presentation</b></p>	<p>JC proposal for criteria for SC based on magnitude of testing, representation of organisations in network, strategic benefits and geographical representation.</p> <p>JC data should remain property of the network and network members in the long term to ensure sustainability. Need processes involving SC for third parties who wish to use data.</p> <p>Network can support organisations that want to perform local or national analyses.</p>	<p>Define criteria for SC composition <i>March</i></p> <p>Put processes in place make decisions on third parties who wish to use COBATEST data. <i>SC meeting April</i></p>
<p><b>Expectations of members</b></p>	<p>Full needs assessment of COBATEST not possible on day of meeting, should be done online after meeting.</p> <p>VM organisations often required to do double reporting, COBATEST could promote the platform to governments to encourage them to use only COBATEST data collection.</p> <p>TK gives Belgium example, CBVCTs will largely be using the COBATEST tool at the request of the Public Health Agency.</p> <p>CK capacity building for counsellors.</p>	<p>Short SurveyMonkey to assess needs of COBATEST members <i>December/January</i></p> <p>Short profiles on COBATEST members <i>2019 members meeting</i></p>

The COBATEST Network and this meeting receive funding from the European Commission 3rd Health Programme and a Gilead grant



Co-funded by  
the Health Programme  
of the European Union



	<p>MT sharing experiences e.g. combo tests. When complete, LF will share results of the WHO utility study of dual syphilis/HIV point of care tests.</p> <p>MA important that COBATEST recognises that data from national focal point on CBVCTs may not be the same as the data collected in the CBVCTs.</p> <p>CK profiling members could be useful to Network and for interpretation of data.</p> <p>VM issues associated with transition “post-Global Fund” in Moldova – national health body asking for client names with tests.</p> <p>MG should tackle issues that impact our services – anti-migrant policies make migrants scared to access care once diagnosed.</p> <p>MK possible reporting conflicts from organisations that receive AHF funding?</p>	
<b>New members</b>	TK presents Plateform Prevention SIDA, which focuses testing among SAM in Brussels and has managed to increase testing in this population by offering glycaemia and blood pressure tests alongside HIV.	Presentation made available online
<b>MSM Checkpoint Toolkit</b>	<p>MKu 5000euro has been made available to improve the toolkit. Improved landing page will improve navigation. Toolkit will be translated to only 4-5 core languages to reduce translation costs. Look at how relevant materials in Clearing House can be made available on toolkit website, how Toolkit website can link to COBATEST’s.</p> <p>The toolkit should only have information on services, not general information on topics (like PrEP etc which is available in other places).</p>	<p>Link MSM Checkpoint Toolkit to COBATEST network website and update members on Toolkit</p> <p>When COBATEST IT provider has changed</p>
<b>COBACohorts update</b>	Presentation available	
<b>HCV screening in CBVCTs in Catalonia</b>	Presentation available	

The COBATEST Network and this meeting receive funding from the European Commission 3rd Health Programme and a Gilead grant



Co-funded by  
the Health Programme  
of the European Union



<p><b>Additional questions to be added to tool</b></p>	<p>Following the discussion in the May 2018 members meeting, a proposal for additional questions was circulated prior to the meeting. Members were reminded that the purpose of the questions is to assess knowledge of and use of PrEP, and prevalence of ChemSex practices. As per the requests of members in May, questions are simplified and few in number. Organisations offering specific services for PrEP and Chemsex may use a separate detailed questionnaire to inform counselling.</p> <p>SM in explanation of PrEP it should be made clear that PrEP is a strategy, not a pill.</p> <p>The question of PrEP being daily or event-driven is not necessary for our aims.</p> <p>The word chemsex should not be used as it is not universally understood – better “Have you used drugs before/during a sex party in the last 12 months?” Followed by Which? And the list of drugs.</p> <p>STI module has not been finalised and was not presented. Some Deutsche AIDS Hilfe organisations are offering STI testing but do not use tool. CJAS offering STI testing, HUHIV will begin to.</p>	<p>Questions will be edited in light of comments and added to data collection tool.</p> <p><i>December 2018</i></p>
<p><b>Other news</b></p>	<p>An abstract using COBATEST Network data has been accepted for an oral presentation at the HepHIV conference in Budapest in January.</p>	<p>Poster will be shared with members.</p> <p><i>January 2019</i></p>

The COBATEST Network and this meeting receive funding from the European Commission 3rd Health Programme and a Gilead grant



Co-funded by  
the Health Programme  
of the European Union

